Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Cost of Revenue (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Cost of Revenue readings, the most recent being $29.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 27.26% year-over-year to $29.7 million, compared with a TTM value of $102.2 million through Dec 2025, down 13.15%, and an annual FY2025 reading of $102.2 million, down 13.16% over the prior year.
  • Cost of Revenue hit $29.7 million in Q4 2025 for Apellis Pharmaceuticals, up from $24.5 million in the prior quarter.
  • The five-year high for Cost of Revenue was $40.9 million in Q4 2024, with the low at $51000.0 in Q4 2021.
  • Median Cost of Revenue over the past 5 years was $16.8 million (2023), compared with a mean of $15.8 million.
  • The sharpest move saw Cost of Revenue skyrocketed 10118.29% in 2023, then tumbled 41.01% in 2025.
  • Year by year, Cost of Revenue stood at $51000.0 in 2021, then skyrocketed by 5635.29% to $2.9 million in 2022, then skyrocketed by 580.75% to $19.9 million in 2023, then soared by 105.18% to $40.9 million in 2024, then dropped by 27.26% to $29.7 million in 2025.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $29.7 million, $24.5 million, and $13.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.